Sumitomo Mitsui Trust Group Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 301,508 shares of the biopharmaceutical company's stock after buying an additional 3,866 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.27% of Regeneron Pharmaceuticals worth $316,957,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company's stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company's stock worth $868,757,000 after purchasing an additional 184,561 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company's stock worth $259,402,000 after purchasing an additional 166,998 shares during the last quarter. Finally, Swedbank AB acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $129,257,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,107.25.
Check Out Our Latest Analysis on REGN
Insider Buying and Selling
In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.48% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals Stock Down 0.7 %
Shares of REGN traded down $5.78 during trading hours on Tuesday, reaching $819.90. The company's stock had a trading volume of 332,441 shares, compared to its average volume of 522,217. The firm has a market cap of $90.10 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 3.13 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $784.96 and a 1-year high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $1,014.52 and a two-hundred day moving average of $1,037.74.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
